HODGKIN’S LYMPHOMA
The
treatment of Hodgkin’s lymphoma has undergone dramatic evolution over the last
30 years. This lymphoma is now widely rec-ognized as a B-cell neoplasm in which
the malignant Reed-Sternbergcells have rearranged VH
genes. In addition, the Epstein-Barr virus genome has been identified in up to
80% of tumor specimens.Complete staging evaluation is required before a
definitive treatment plan can be made. For patients with stage I and stage IIA
disease, there has been a significant change in the treatment approach.
Initially, these patients were treated with extended-field radiation therapy.
However, given the well-documented late effects of radiation therapy, which
include hypothyroidism, an increased risk of secondary cancers, and coronary
artery disease, combined-modality therapy with a brief course of combination
chemotherapy and involved field radiation therapy is now the recommended
approach. The main advance for patients with advanced stage III and IV
Hodgkin’s lymphoma came with the development of MOPP (mechlorethamine,
vincristine, procarba-zine, and prednisone) chemotherapy in the 1960s. This
regimen resulted initially in high complete response rates, on the order of
80–90%, with cures in up to 60% of patients. More recently, the
anthracycline-containing regimen termed ABVD (doxorubicin, bleomycin,
vinblastine, and dacarbazine) has been shown to be more effective and less
toxic than MOPP, especially with regard to the incidence of infertility and
secondary malignancies. In general, four cycles of ABVD are given to patients.
An alternative regimen, termed Stanford V, utilizes a 12-week course of
combination che-motherapy (doxorubicin, vinblastine, mechlorethamine,
vincristine, bleomycin, etoposide, and prednisone), followed by involved
radiation therapy.With all of these regimens, over 80% of previously
untreated patients with advanced Hodgkin’s lymphoma (stages III and IV) are
expected to go into complete remission, with disappearance of all
disease-related symptoms and objective evidence of disease. In general,
approximately 50–60% of all patients with Hodgkin’s lymphoma are cured of their
disease.
Related Topics
Privacy Policy, Terms and Conditions, DMCA Policy and Compliant
Copyright © 2018-2024 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.